Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
In this case study, Dr. Papasavva describes her laboratory’s journey from traditional thalassemia testing to state-of-the-art NGS technology and what a difference this has made in their daily work.
Infographic
This infographic details how next-generation sequencing
(NGS) can be used to help provide fast and accurate thalassemia diagnosis.
Thalassemia is an inherited blood disorder with a worldwide prevalence of nearly 300,000 people diagnosed per year. As the most common hemoglobinopathy, it is a major cause of disability and premature mortality around the world. However, if the disease is diagnosed correctly, treatment can
begin promptly, which can help prevent permanent damage caused by excessive iron build-up and provide patients with a better quality of life. The overall incidence of thalassemia has decreased due to successful prevention programs in areas of high prevalence. However, migration and the resulting shifting demographics have seen the disease
occurring in regions not previously endemic.
The discovery of more variants makes it challenging for clinicians and laboratories to diagnose and manage appropriately. These regions would benefit from a test that
provided comprehensive genetic profiling with an efficient workflow.
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...
Read More